Oligonucleotide Synthesis Market to Uplift USD 20.31 Billion by 2034

Oligonucleotide Synthesis Market Size, Shares and Trends Insight 2023 - 2034

The global oligonucleotide synthesis market size is estimated at US$ 5.59 billion in 2024 and is projected to grow to US$ 20.31 billion by 2034, rising at a compound annual growth rate (CAGR) of 13.78% from 2024 to 2034. The growing demand for the biotechnology industry drives the market’s growth.

Unlock Infinite Advantages: Subscribe to Annual Membership

Major Key Insights of the Oligonucleotide Synthesis Market

• By region, North America dominated the oligonucleotide synthesis market share by 41.02% in 2023.
• By region, Asia Pacific is expected to grow at the fastest rate during the forecast period.
• By product & service, the services segment held the largest share of the market in 2023.
• By application, the PCR primers segment dominated the market in 2023.

Oligonucleotide Synthesis Market: Wide Applications in Life Science

The chemical process via which nucleotides are precisely joined to create the required sequencing result is known as oligonucleotide synthesis. Packed-bed columns are frequently employed in continuous solid-phase synthesis for the production of oligonucleotides. A batch slurry reaction is used in certain situations. As sequence-specific binding agents, oligonucleotides are employed in a wide range of biological and forensic applications to identify the presence of a particular target DNA sequence. Throughout history, modified oligos have played a significant role in a wide range of life science applications, particularly in clinically-based settings such as molecular diagnostics and therapies.

How can AI Improve the Oligonucleotide Synthesis Market?

After targets are found, the creation and alteration of therapeutic oligonucleotides take center stage. An important element played by artificial intelligence is that which our partner Sylentis uses in their exclusive sirFinder program. Sophisticated algorithms examine extensive datasets to forecast the effectiveness of the oligonucleotides that are developed. With the help of tools like these, gene therapy may now be carried out more accurately and quickly, reaching new heights in the process.

For instance,

• In March 2022, with the aim of creating precision medications, Creyon Bio, an expert in oligonucleotide research, raised $40 million in a series A fundraising round headed by DCVC Bio and Lux Capital. Former executives from Ionis Pharmaceuticals, a leader in antisense oligonucleotide treatments, lead Creyon. In order to determine engineering principles and design guidelines for medications that treat both individual patients and sizable patient groups, it intends to use machine learning to proprietary data sets.

Top Companies in the Oligonucleotide Synthesis Market

• Thermo Fisher Scientific, Inc.
• Biolegio
• Agilent Technologies
• Bio-synthesis
• Dharmacon Inc.
• Kaneka Eurogentec S.A
• Merck KGaA
• LGC Biosearch Technologies
• Codexis Inc.
• Danaher Corporation
• Twist Bioscience
• Asahi Kasei Bioprocess (AKB)

AKB’s Contribution to the Oligonucleotide Synthesis Market

Codexis Inc. Contribution to the Oligonucleotide Synthesis Market 

Genetic Disorders is Driving the Oligonucleotides Synthesis Market 

The market for oligonucleotide synthesis is significantly driven by the rising incidence of genetic illnesses, which include ailments like cancer, uncommon diseases, and genetic abnormalities. According to World Health Organization (WHO) research, millions of individuals worldwide are significantly impacted by genetic illnesses. To produce targeted medicines and molecular diagnostics specific to particular genetic variants, oligonucleotides are essential. The need for oligonucleotide-based therapies is growing as our understanding of the genetic underpinnings underlying disease processes becomes more profound.

For instance,

• Because they affect less than 1 in 2000 individuals in any particular WHO region, rare illnesses are, by definition, uncommon. Despite this, there are approximately 7000 distinct types of rare diseases worldwide, making their burden significant. There are 300 million persons with rare illnesses in the world today. Roughly 95% of uncommon illnesses are incurable, and over 70% of them affect children. Roughly 80 percent of rare illnesses have a genetic origin.

Difficulty in Synthesizing Large Strand Restraint

Because the number of mistakes increases with the length of the oligonucleotide being synthesized, side reactions provide practical limits on the length of synthetic oligonucleotides, up to around 200 nucleotide residues.

Large Scale Manufacturing is the Future of Oligonucleotide Synthesis Market

Up until recently, traditional solid-phase synthesis has successfully met the need for oligonucleotide-based medications. Nonetheless, several items that are now undergoing advanced phases of clinical studies are anticipated to have a collective demand in metric tons in the near future. Process chemists now consider it of utmost importance to manufacture these goods on a massive scale. Clearly, significant efforts are being made to create a scalable, cost-effective, green chemical process that is environmentally safe and effective for oligonucleotide production.

The Service Segment Dominated the Market in 2023

By product & service, the services segment held the largest share of the oligonucleotide synthesis market in 2023. Numerous businesses provide custom oligo synthesis services for a range of molecular biology applications. The remarkable rate of advancement in genomic research methodologies highlights the demand for quick, affordable, and high-quality oligonucleotides. Chromatography is a method that uses differential adsorption on an adsorbent surface to separate the constituents of a mixture. Furthermore, it could be advantageous to characterize the finished product before using it. Mass spectrometry, frequently in conjunction with chromatography, is an effective technique for this.

For instance,

• In March 2023, the independent oligo factory, which produces bespoke oligonucleotides on a large scale, said today that it is relocating its headquarters to Holliston, Massachusetts, to construct a new oligo production facility. Oligo Factory's next generation of synthesizers will have nearly 13,000 square feet of combined bench space, offices, and labs in the new building, which provides a 12x increase in manufacturing capacity.

The PCR Primers Segment Held the Largest Share in 2023

By application, the PCR primers segment dominated the oligonucleotide synthesis market in 2023. The oligonucleotide synthesis process, which uses PCR-based amplification, is a crucial technique in molecular biology because it offers a flexible way to amplify DNA and modify it to create distinct molecules. Research on gene expression, genetic testing, and cloning all depend on this methodology.

North America Dominated Due to Strong Biotechnology Industry

By region, North America dominated the oligonucleotide synthesis market share by 41.02% in 2023. Influential research and development expenditures, in conjunction with the region's thriving biotechnology and pharmaceutical industries, have driven market developments. Further driving the rising need for oligonucleotides is the boom in genomic research and gene therapy projects, including those started by top universities. North America has played a major role in propelling the oligonucleotide synthesis market's notable expansion, as evidenced by its well-established infrastructure, positive regulatory environment, and increased awareness of genetic abnormalities. Strong medical facilities, a large number of major business leaders, an increase in cases of viral diseases, and a rise in research projects. These elements strengthen the area's position as a pioneer in the development and use of oligonucleotide synthesis methods.

Asia Pacific is Expected to Grow at Fastest CAGR During 2024-2033

By region, Asia Pacific is expected to grow at the fastest rate during the forecast period. Advances in genomic research and the broad use of PCR and sequencing technology are the main drivers of this explosive expansion. As they grow their business potential, genomics is becoming increasingly important to China, India, and Japan. A growing number of product approvals and launches are also taking place in the area, which is helping the oligonucleotide synthesis market grow.

The Genomics India Conference is returning! This conference, the fourth in the Genomics India series, will showcase cutting-edge research into the most recent developments in genetic technology, with an emphasis on disseminating ground-breaking discoveries. For academics, physicians, and other professionals who want to keep current on the most recent findings and advancements in the field of genetics, GIC2024 is an excellent platform. There will be a ton of subjects discussed, such as the use of genomics in the fields of infectious diseases, cancer genomics, inherited diseases, diagnostics, biopharma, vaccine development, and agriculture. A stellar lineup of speakers and panelists, including well-known figures from the Indian and global diaspora, will be featured at the conference. Their talks will be distributed across three days and several sessions.

India is also focusing on sequencing human genomes, which will continuously require the synthesis of oligonucleotides. Till today, a lot of samples have been collected and used for genome sequencing. There are biobanks across India that save and reserve samples from different ethnicities.

Recent Developments in the Oligonucleotide Synthesis Market

• In July 2024, Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) developed a method for synthesizing single-stranded RNA. The method is described in a new paper titled "Template-independent enzymatic synthesis of RNA oligonucleotides" that was published in Nature Biotechnology. EnPlusOne Biosciences is commercializing the technique, which creates single-stranded RNA without needing a template sequence and with efficiencies and purities equivalent to conventional chemical synthesis utilizing water and enzymes.
• In May 2024, Molecular Assemblies, Inc. (hereafter referred to as "MAI" or the "Company"), a pioneer and leader in the field of enzymatic DNA synthesis, licensed its fully enzymatic synthesizer (FESTM) technology for on-site synthesis under the company's Partnering Program. To fuel a new, quickly emerging generation of treatments and diagnostics, FES technology speeds the manufacture of lengthy, clean, and precise DNA.
• In March 2023, the world's longest DNA oligonucleotide ever reported to be generated in a single synthesis was successfully synthesized de novo, according to Ansa Biotechnologies, Inc., a leader in next-generation DNA synthesis. The complex features of the 1005 base sequence, which include strong secondary structures and a high GC content, make it difficult to synthesize the sequence using traditional methods that require the assembly of shorter oligonucleotides. This sequence encodes a crucial portion of an AAV vector used for the development of gene therapy.

Segments Covered in the Report

By Product & Service

• Oligonucleotides
  • DNA
    • Column-based
    • Array-based
  • RNA
    • By Technology
      • Column-based
      • Array-based
    • By Type
      • Short RNA Oligos (<65 nt)
      • Long RNA Oligos (>65 nt)
      • CRISPR (sgRNA)
• Equipment/Synthesizer
• Reagents
• Services
  • DNA
    • Custom Oligo Synthesis Services
      • 25 nmol
      • 50 nmol
      • 200 nmol
      • 1000 nmol
      • 10000 nmol
    • Modification Services
    • Purification Services
  • RNA
    • Custom Oligo Synthesis Services
      • 25 nmol
      • 100 nmol
      • 1000 nmol
      • 10000 nmol
    • Modification Services
    • Purification Services

By Application

• PCR Primers
  • Academic Research Institutes
  • Diagnostic Laboratories
  • Pharmaceutical - Biotechnology Companies
• PCR Assays & Panels
  • Academic Research Institutes
  • Diagnostic Laboratories
  • Pharmaceutical - Biotechnology Companies
• Sequencing
  • Academic Research Institutes
  • Diagnostic Laboratories
  • Pharmaceutical - Biotechnology Companies
• DNA Microarrays
  • Academic Research Institutes
  • Diagnostic Laboratories
  • Pharmaceutical - Biotechnology Companies
• Fluorescence In Situ Hybridization (FISH)
  • Academic Research Institutes
  • Diagnostic Laboratories
  • Pharmaceutical - Biotechnology Companies
• Antisense Oligonucleotides
  • Academic Research Institutes
  • Diagnostic Laboratories
  • Pharmaceutical - Biotechnology Companies
• Other Applications

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait